Clindamycin
| Subclass of | lincosamides  |
|---|---|
| Get use | Medication |
| Chemical formula | C₁₈H₃₃ClN₂O₅S |
| Canonical SMILES | CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl |
| Isomeric SMILES | CCC[C@@H]1C[C@H](N(C1)C)C(=O)NC([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)C(C)Cl |
| Route of administration | oral administration, parenteral route of administration, intravaginal administration |
| Legal status (medicine) | boxed warning |
| Pregnancy category | Australian pregnancy category A, US pregnancy category B |
| LiverTox likelihood score | LiverTox toxicity likelihood category B |
| Get characteristic | bitterness |
| Subject has role | protein synthesis inhibitor, antibiotic, WHO essential medicines |
| WHO Aware Classification | access |
Clindamycin be a lincosamide antibiotic medication dem use for de treatment of a number of bacterial infections, wey dey include osteomyelitis (bone) anaa joint infections, pelvic inflammatory disease, strep throat, pneumonia, acute otitis media (middle ear infections), den endocarditis.[1] E sanso fi be used to treat acne,[1][2] den sam cases of methicillin-resistant Staphylococcus aureus (MRSA).[3] In combination plus quinine, e fi be used to treat malaria.[1][2] E be available by mouth, by injection into a vein, den as a cream anaa a gel to be applied to de skin anaa insyd de vagina.[1][2][4][5][6]
Common side effects dey include nausea den vomiting, diarrhea, skin rashes, den pain at de site of injection.[1] E dey increase de risk of hospital-acquired Clostridioides difficile colitis about fourfold den thus only be recommended for use wen oda antibiotics no be appropriate.[1][7] E dey appear to be generally safe insyd pregnancy.[1] E be of de lincosamide class den dey work by blocking bacteria from making protein.[1]
Na dem first make clindamycin insyd 1966 from lincomycin.[8][9] E dey on de World Health Organization's List of Essential Medicines.[10] E be available as a generic medication.[11][12] Insyd 2023, na e be de 149th most commonly prescribed medication insyd de United States, plus more dan 3 million prescriptions.[13][14]
References
[edit | edit source]- 1 2 3 4 5 6 7 8 "Clindamycin (Systemic)". The American Society of Health-System Pharmacists. Archived from the original on 12 August 2021. Retrieved 19 December 2021.
- 1 2 3 Leyden JJ (2006). Hidradenitis suppurativa. Berlin: Springer. p. 152. ISBN 978-3-540-33101-8. Archived from the original on 8 September 2017.
- ↑ Daum RS (July 2007). "Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus". N. Engl. J. Med. 357 (4): 380–90. doi:10.1056/NEJMcp070747. PMID 17652653.
- ↑ "Xaciato- clindamycin phosphate gel". DailyMed. Retrieved 24 December 2021.
- ↑ "Clindamycin phosphate- clindamycin phosphate gel usp, 1% gel". DailyMed. Retrieved 19 December 2021.
- ↑ "Daré Announces FDA Approval of Xaciato (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis". Daré Bioscience (Press release). 7 December 2021. Retrieved 19 December 2021.
- ↑ Thomas C, Stevenson M, Riley TV (2003). "Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review". J Antimicrob Chemother. 51 (6): 1339–50. doi:10.1093/jac/dkg254. PMID 12746372.
- ↑ Smieja M (January 1998). "Current indications for the use of clindamycin: A critical review". The Canadian Journal of Infectious Diseases. 9 (1): 22–8. doi:10.1155/1998/538090. PMC 3250868. PMID 22346533.
- ↑ Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life (7 ed.). John Wiley & Sons. 2014. p. 162. ISBN 978-1-118-81951-7. Archived from the original on 8 September 2017.
- ↑ World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ↑ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 108. ISBN 978-1-284-05756-0.
- ↑ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
- ↑ "Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
- ↑ "Clindamycin Drug Usage Statistics, United States, 2014 - 2023". ClinCalc. Retrieved 18 August 2025.
External links
[edit | edit source]
- Clinical trial number NCT04370548 for "DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)" at ClinicalTrials.gov